바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.60 No.2
Citation Share

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2006, v.60 no.2, pp.180-186




& (2006). . Tuberculosis & Respiratory Diseases, 60(2), 180-186.
  • Downloaded
  • Viewed
PDF Download

Abstract

Background : Para-aminosalicylic acid(PAS) is a 2nd-line drug that can cause severe adverse reactions leading to poor patient compliance. This study evaluated the relapse rate according to the discontinuance of PAS at a certain point after bacteriological conversion during the course of chemotherapy for multidrug-resistant tuberculosis(MDR-TB).Methods : 42 out of 452 MDR-TB patients were enrolled in this study. All subjects were receiving chemotherapy including PAS at National Masan TB Hospital between Jan. 1, 2000 and Dec. 31, 2001. The relapse rate was evaluated after the discontinuance of PAS from their initial regimen as a result of the severe adverse reactions at a certain point after the bacteriological conversion during the course of chemotherapy for MDR-TB.Results : The male to female ratio was 2.5:1, and the mean age was 47.2 years old. The average number of past histories, used drugs and resistant drugs was 1.2, 3.9 and 4.3. The mean number of sensitive drugs included in the inirial regimen was 3.9. The mean time for bacteriological conversion and discontinuance of the PAS was 2.3 months after initiating treatment and 6 months after bacteriological conversion, respectively. There was no relapse after discontinuing PAS during a mean follow up period of 31.6 months.Conclusion : PAS may be discontinued in the cases of serious gastrointestinal problems approximately 6 months after bacteriological conversion without concern about relapse.(Tuberc Respir Dis 2006; 60: 180-186)

keywords
Para-aminosalicylic acid(PAS), Multidrug-resistant tuberculosis, Compliance, Para-aminosalicylic acid(PAS), Multidrug-resistant tuberculosis, Compliance

Reference

1.

Kritski AL, (1997) Retreatment tuberculosis cases:factors associated with drug resistance and adverse outcomes,

2.

Bechan S, (1997) Directly observed therapy for tuberculosis given twice weekly in the workplace in urban South Africa,

3.

Goble M, (1993) Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin,

4.

Weis SE, (1994) The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis,

5.

Pearce SJ, (lancet1974) Follow-up of patients with pulmonary tuberculosis adequately treated by chemotherapy,

6.

Singapore Tuberculosis Service/Birtish Medical Research Council, (1988) Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis,

7.

Burman WJ, (1997) Noncompliance with directly observed therapy for tuberculosis:epidemiology and effect on the outcome of treatment,

8.

Jarvis B, (1998) Rifapentine,

9.

Addington WW, (1979) Patient compliance:the most serious remaining problem in the control of tuberculosis in the United States,

10.

Davidson PT, (1992) Drug treatment of tuberculosis:1992,

11.

Kilpatrick GS, (1987) Compliance in relation to tuberculosis,

12.

Cueno WD, (1989) Enhancing patient compliance with tuberculosis therapy, Clin Chest Med

13.

Snider DE Jr, (1992) The new tuberculosis,

14.

Bloch AB, (1999) Completion of tuberculosis therapy for patients reported in the United States in 1993,

15.

American Thoracic Society, (2003) Treatment of tuberculosis,

16.

Centers for Disease Control, (1982) Patients with recurrent tuberculosis,

17.

la Raja M, (1997) Antituberculosis drug-resistance surveillance as a tool for tuberculosis control programmes,

18.

Strull GE, (1995) Tuberculosis:diagnosis and treatment of resurgent disease,

19.

Canetti G, (1963) Mycobacteria:laboratory methods for testing drug sensitivity and resistance,

20.

Park SK, (2004) Self-administered,standardized regimens for multidrug-resistant tuberculosis in South Korea,

21.

Kim HK, (2001) Ambulatory treatment of multidrug-resistant tuberculosis patients at a chest clinic,

22.

Volmink J, (2000) Directly observed therapy and treatment adherence,

23.

Mangura B,, (2002) Directly observed therapy(DOT) is not the entire answer: an operational cohort analysis,

24.

Bernheim F, (1940) Effect of salicylates on oxygen uptake of tubercle bacillus,

25.

Lehman J, (1946) Para-aminosalicylic acid in the treatment of tuberculosis,

26.

2nd ed, (1986) Antibiotics in laboratory medicine,

27.

Rengarajan J, (2004) The folate pathway is a target for resistance to the drug para-aminosalicylic acid(PAS)in mycobacteria,

28.

Kucers A, (1979) The use of antibiotics, Heinemann

29.

de la Huerga J, (1961) Out-patient acceptance of PAS transactions of the 20th research conference in pulmonary diseases Veterans Administration Department of Medicine and Surgery,

30.

Ormerod LP, (2005) Multidrug-resistant tuberculosis(MDR-T B) epidemiology, prevention and treatment,

Tuberculosis & Respiratory Diseases

e-Submission OA Policy